What we're reading, February 10, 2016: 2 companies change how consumers purchase medicines online; CMS memo reveals the government is mulling changes to Medicare reimbursement; and Johns Hopkins will transplant HIV-positive organs to HIV-positive recipients.
Transparency is often cited as one of the best ways lower drug prices, and now 2 companies are pulling back the curtain to change how consumers purchase medicines. In a new article, The New York Times highlighted GoodRx, which collects drug prices and connects consumers with coupons, and Blink Health, which allows consumers to purchase drugs online and pick them up at nearly any pharmacy. The price quotes on these sites are for generic drugs, but they cannot help much with brand-name drugs.
A new memo from CMS has revealed that there may be changes coming for how Medicare pays physicians. However, the document has since been taken down from CMS’ website, and its release called “premature,” reported Bloomberg Business. According to the memo, a new payment system would allow reimbursement to doctors for the drugs they administer to vary by geographic location.
Johns Hopkins will become the first hospital in the United States to transplant organs from HIV-positive donors to HIV-positive recipients. Until recently, such use of organs from HIV-positive individuals was illegal in the US, but South Africa has been allowing these transplants for several years with positive outcomes, according to The Washington Post. The US passed a law in late 2013 legalizing the use of HIV-positive organs for HIV-positive recipients.
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen